Citi Reiterates Sell Rating on PTC Therapeutics (PTCT), 'PIVOT-HD Data Update Supportive, But Expectations Measured to this Point'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
PTC Therapeutics (PTCT) PT Raised to $32 at BofA Securities
June 21, 2024 5:37 AM EDTBofA Securities analyst Tazeen Ahmad raised the price target on PTC Therapeutics (NASDAQ: PTCT) to $32.00 (from $25.00) while maintaining a Underperform rating.
The analyst comments "PTCT announced interim 12-mos results from Part 2 of the ph 2 PIVOT-HD trial evaluating PTC518 in Huntingtons disease (HD). The... More
Goldman Sachs Reiterates Sell Rating on PTC Therapeutics (PTCT)
June 21, 2024 5:27 AM EDTGoldman Sachs analyst Paul Choi reiterated a Sell rating and $32.00 price target on PTC Therapeutics (NASDAQ: PTCT).
The analyst comments "Positive biomarker signals from PIVOT-HD program as FDA lifts clinical hold. This morning, PTCT announced interim results from its Phase 2 PIVOT-HD study of PTC-518 at 12 months in patients with HD. Treatment with the oral small... More
JPMorgan on PTC Therapeutics (PTCT): 'Despite Notable Unknowns for Clinical & Regulatory Outlook, 12-mo PIVOT-HD Update Solidly Encouraging on All Fronts'
June 20, 2024 1:12 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $53.00 price target on PTC Therapeutics (NASDAQ: PTCT).
The analyst comments "With second interim data showing continued HTT knockdown in both blood and CSF from 12-month PTC-518 dosing, coupled with an ongoing favorable safety/tolerability profile, we view this mornings PIVOT-HD update as the best-case scenario for the asset into the readout. That... More
